Remdesivir Efficacy In Management Of COVID-19 Patients
Remdesivir Efficacy In Management Of COVID-19 Patients
The study is open label randomized interventional phase 3 clinical trial. Patients with
 confirmed Covid-19 cases who was hospitalized in Two university isolation hospitals (Ain
 Shams University and Assiut University ) assigned hospitals for isolation.
The study is open label randomized interventional phase 3 clinical trial. Patients with
 confirmed Covid-19 cases who was hospitalized in Two university isolation hospitals (Ain
 Shams University and Assiut University ) assigned hospitals for isolation.

 The included patients receive. Intervention group: Remdesivir loading dose of 200 mg
 intravenously followed by 100 mg/day intravenously for 5 to 10days + Methylprednisolone
 1-2mg/kg for 5-7 days Control group: standard of care without Remdesivir
Inclusion Criteria:

 Adult 18 -80 years old Must have laboratory confirmed COVID-19(A patient with laboratory
 confirmation (Positive RT-PCR) of COVID-19 infection, irrespective of clinical signs and
 symptoms according to Ain Shams University Hospitals Consensus Statement on Management of
 Adult COVID-19 Patients.

 Must have severe or immediately life-threatening COVID-19,

 -  Severe disease is defined as:

 -  Dyspnea,

 -  Respiratory frequency ≥ 30/min,

 -  Blood oxygen saturation ≤ 93%,

 -  Partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300,
 and/or lung infiltrates > 50% within 24 to 48 hours

 -  Life-threatening disease is defined as:

 -  respiratory failure,

 -  septic shock, and/or

 -  multiple organ dysfunction or failure

 -  Must provide informed consent by patient or his/her legal guardian or Professional
 Legal Representative

 Exclusion Criteria:

 -  Mild to moderately affected COVID 19 confirmed patients.

 -  pregnancy, lactation.

 -  known hepatic failure.

 -  Patient who is not likely to comply to study procedures.

 -  Creatine clearance <30 ml/min.

 -  Elevated transaminases > 5 fold ULN.